GSA Capital Partners LLP Buys Shares of 14,986,947 Gossamer Bio, Inc. $GOSS

GSA Capital Partners LLP bought a new stake in shares of Gossamer Bio, Inc. (NASDAQ:GOSS) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 14,986,947 shares of the company’s stock, valued at approximately $2,467,000. GSA Capital Partners LLP owned about 6.39% of Gossamer Bio at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Kalehua Capital Management LLC bought a new stake in shares of Gossamer Bio in the 1st quarter worth approximately $3,363,000. State Street Corp grew its stake in Gossamer Bio by 139.7% during the 4th quarter. State Street Corp now owns 9,310,969 shares of the company’s stock worth $28,864,000 after buying an additional 5,427,302 shares during the last quarter. Corient Private Wealth LLC increased its position in Gossamer Bio by 19,123.7% in the fourth quarter. Corient Private Wealth LLC now owns 3,845,885 shares of the company’s stock worth $11,922,000 after buying an additional 3,825,879 shares during the period. Millennium Management LLC increased its position in Gossamer Bio by 629.3% in the third quarter. Millennium Management LLC now owns 3,619,329 shares of the company’s stock worth $9,519,000 after buying an additional 3,123,081 shares during the period. Finally, Bank of America Corp DE increased its position in Gossamer Bio by 4,196.2% in the third quarter. Bank of America Corp DE now owns 2,881,904 shares of the company’s stock worth $7,579,000 after buying an additional 2,814,824 shares during the period. 81.23% of the stock is currently owned by institutional investors and hedge funds.

Gossamer Bio Price Performance

GOSS opened at $0.15 on Friday. Gossamer Bio, Inc. has a 12 month low of $0.11 and a 12 month high of $3.87. The stock has a market cap of $36.19 million, a P/E ratio of -0.22 and a beta of 2.04. The stock’s 50 day moving average price is $0.17 and its 200 day moving average price is $0.57.

Gossamer Bio (NASDAQ:GOSS) last announced its earnings results on Thursday, August 13th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.04. The business had revenue of $9.24 million for the quarter, compared to the consensus estimate of $3.63 million. Equities analysts anticipate that Gossamer Bio, Inc. will post -0.39 EPS for the current year.

Wall Street Analysts Forecast Growth

GOSS has been the subject of several analyst reports. HC Wainwright reissued a “buy” rating on shares of Gossamer Bio in a report on Monday, July 27th. Weiss Ratings cut shares of Gossamer Bio from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, May 19th. Finally, Leerink Partners upgraded shares of Gossamer Bio from a “market perform” rating to an “outperform” rating and set a $1.00 price objective on the stock in a research report on Tuesday, July 28th. Four research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $3.20.

Gossamer Bio Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.